Stock RXI PHARMACEUTICALS CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News RXi Pharmaceuticals Corp OTC Bulletin Board

Equities

US74979C1053

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for RXi Pharmaceuticals Corp
Jul. 02 Phio Pharmaceuticals Board Approves 1-For-9 Reverse Stock Split MT
May. 28 Phio Pharmaceuticals Corp. Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
AQ
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
NE
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
AQ
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
NE
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
NE
Reverse Split: 1 of 9
FA
Phio Pharmaceuticals Board Approves 1-For-9 Reverse Stock Split
MT
Phio Pharmaceuticals Announces Reverse Stock Split
NE
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
NE
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762
AQ
Phio Pharmaceuticals Corp. Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762
CI
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
NE
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
NE
Phio Pharmaceuticals Files $100 Million Mixed Shelf
MT
Phio Pharmaceuticals Secures New Investor
AQ
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
AQ
Phio Pharmaceuticals Doses 1st Group in Skin Cancer Treatment Study
MT
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
AQ
Phio Pharmaceuticals Corp Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
CI
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHIO Stock
  4. Stock
  5. News RXi Pharmaceuticals Corp